Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Accounts Payables · Q4 FY2025 · quarter ended Dec 2025

Accounts payables declines year over year

Q4 FY2025 accounts payables of $26K (cash outflow) fell 87.9% year over year.

Context

  • Accounts payables increased in 1 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$26K-107.7% QoQ
Last fiscal yearDec 2025
$398K+199.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-87.9%——
1 year+199.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
398K USD
Year-over-year change
+199.3%

Accounts Payables vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 accounts payables of $398K is the 7th largest of the 8 companies compared; the peer median is $6.37K.
  • Its year-over-year change of +199.3% is the highest of 6, against a peer median of -49.2%.
PLYX Competitors Peer median
Accounts Payables for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTHSPelthos Therapeutics Inc.LTM Mar 2026$3.81M +112.4%+48.6%13.8%
JBIOJade Biosciences, Inc.LTM Mar 2026$2.84M —-35.9%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.7M +135.6%—5477.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$1.4M ———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$793K -49.2%-33.2%2.8%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$457K -171.4%——
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$398K +199.3%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026$6.37K -100.5%—0.1%
Peer median (excluding PLYX) $6.37K-49.2%-33.2%8.3%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.